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ABSTRACT 
 
Many herbs are believed to be beneficial in curing diseases, in addition to improving general health and well-
being. With the booming of many herbal and traditional medicines into local markets, it is feared that the 
harmful side effects might prevail over their potential benefits as there is a lack of or even no scientific basis 
for the belief. The popularity of these medicines in the modern age is proliferated by the rapid growth of the 
internet usage worldwide vis-à-vis aggressive online marketing by the manufacturers, producers, retailers and 
sellers. These categories of medicines generally fall under the purview of various regulations such as the 
Control of Drugs and Cosmetics Regulations 1984, Sale of Drug Act 1952, Poison Act 1952, and the 
Advertisement and Sale Act 1956. Despite these regulations, production and sale of traditional medicines 
might pose some issues in relation to their safety to the consumers as they contain some new active ingredient 
of plant extracts which are chemicals that have the potential of causing adverse implication to health, similar 
to those purified medications. Generally, registration requirements for food supplements are not as stringent 
as those made applicable for pharmaceutical products and hence, many herbal and traditional medicines are 
registered under the former rather than the latter categories. Setting on this background, this paper seeks to 
examine the current legal framework regulating herbal and traditional medicines in Malaysia, with a special 
emphasis on the issues and challenges revolving around them. This paper uses qualitative research method, 
that is a content analysis of the existing literature from journals, articles, periodicals and various websites. 
Doctrinal analysis is applied to examine the relevant laws in selected jurisdictions, such as the United 
Kingdom, European Union, Australia and Japan, with the aim of emulating the most suitable, best practice 
from these countries. This paper concludes with some suggestions such as imposing the requirement of 
clinical evidence and adopting a systematic post-marketing surveillance to overcome the problems and 
weaknesses of the current legal mechanism in regulating products of herbal and traditional medicines. 
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1. INTRODUCTION 
 
Herbal and traditional medicines which form part of complementary medicine have become the 
popular choice both in developed and developing countries. The popularity of these medicines in 
the modern age is proliferated by the booming and rapid growth of the internet usage worldwide 
vis-à-vis aggressive online marketing by the manufacturers, producers, retailers and sellers. 
Historically, the usage and consumption of herbal and traditional medicines could be traced back 
to the practice of ancient civilization and thus an integral part of the daily life, with the aim of 
improving well-being and health (Sooi & Keng, 2013). In term of global statistics, annually, such 
medicines were reported to reach USD60bil (approximately RM192bil) and the figure is projected 
to grow at a steady rate. This figure is estimated to grow up to 20 times over the next few decades. 
The estimated figure as released by the World Bank was US$5tril, or RM16tril in 30 years, that is 
by the year 2050. Such a steady increase in use and consumption has prompted concerns about the 
safety and efficacy of traditional and herbal medicine (Colwell, 2016). 
 
As a country with very rich biodiversity resources, the herbal products industry has been identified 
as one of important industry to drive Malaysia’s emerging bio-economy. In fact, herbal medicine 
industry in Malaysia if properly researched and work on, would be able to generate a lucrative 
income as the potential of the existing species of plants are enormous. It was estimated that ten 
percent of the total 20,000 species of plants if properly researched and developed, could be 
produced as a useful alternative medicine (Shah, 2017). To achieve the mission, the Government 
has made a serious effort to spur the growth of the herbal industry by placing it under Entry Point 
Project 1 (EPP1) of Agriculture, which is one of 12 National Key Economic Areas (Heng, 2015). 
 
For millions of people in developing countries, traditional and herbal medicinal products remain 
as a very popular choice as they are perceived as the most accessible and affordable treatment 
option (Colwell, 2016). Other than local consumers’ traditional strong belief on herbal and 
traditional medicines, some of the reasons which are associated with the escalating popularity of 
these products are; population from the middle and high income group are becoming more health 
conscious and thus they have resorted to these complementary medicines to maintain a healthy 
lifestyle. This scenario is supported by an aggressive marketing via various social media, including 
those traditional products and supplements which are promoted as 'natural' or herbal based. Other 
than the above two groups of population, complementary medicines such as traditional and herbal 
products have also become the preferred choice for lower income group for some reasons such as 
affordability, cultural and surrounding influences (Milton, 2008).  
 
Some supporting statistics in relation to the above scenario can be seen from a survey which was 
carried out in 2005 by the Malaysian Health Ministry. The survey found that 69.4% respondents 
were users and consumers traditional or complementary medicines in their whole life and hence it 
reflects the lifestyle of Malaysians generally. In terms of the number of registered products under 
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the category of traditional medicines, the Malaysian Health Ministry’s Drug Control Authority 
disclosed that up to December 2007, the cumulative figure comprised of 18,200 which is 46.5%, 
while prescription medicines accounted for 30.2% and 23.3% was from over-the-counter 
medicines. The substantial portion of registered traditional medicines is parallel to the concept of 
‘supply and demand’, thus explaining the booming of such products in local market (Colwell, 
2016). World Health Organization (WHO) estimated that the traditional and complementary 
medicines industry in Malaysia could generate the total sales of RM1000 million annually (WHO, 
2001). Undoubtedly, traditional and complementary medicines contribute to a substantial portion 
of the Malaysian health sector, affecting the public at large. 
 
 
2. TERMINOLOGIES 
 
The terms traditional, complementary and herbal medicine are succinctly defined by the World 
Health Organization (WHO). These three terms are closely related and it is not surprising that they 
may be used interchangeably. According to WHO, as provided on its website, traditional medicine 
generally refers to, “the sum total of the knowledge, skill, and practices based on the theories, 
beliefs, and experiences indigenous to different cultures, whether explicable or not, used in the 
maintenance of health as well as in the prevention, diagnosis, improvement or treatment of physical 
and mental illness” (WHO, 2018). The broad concept of traditional medicines seems to encompass 
diverse aspect of cultural varieties across the globe.  
 
The terms “complementary medicine” or “alternative medicine” in turn denotes “a broad set of 
health care practices that are not part of that country’s own tradition or conventional medicine and 
are not fully integrated into the dominant health-care system”. This definition emphasizes on the 
practices which exist concurrently with modern health care system but remain as a distinct regime.  
 
The most significant terminology is herbal medicine which is defined “to include herbs, herbal 
materials, herbal preparations and finished herbal products, that contain as active ingredients parts 
of plants, or other plant materials, or combinations”. This is in fact the focus of this paper, ie legal 
issues and challenges revolving around these products, which have now flooded the local markets 
and become a very popular choice among consumers. 
 
 
3. LAWS GOVERNING TRADITIONAL AND HERBAL MEDICINES IN MALAYSIA 
 
Traditional medicines, herbal products, and supplements in Malaysia come under the purview of a 
number of legislations such as the Control of Drug and Cosmetic Regulations 1984, Poison Act 
1952, Sale of Drug Act 1952, Advertisement and Sale Act 1956 and Protection of Wild Life Act 
1972. It is to be noted that these legislations are applicable for all kinds of sale and marketing of 
the medicines, inclusive of online and offline sale. The Sale of Drugs Act 1952 for instance, 
governs the sale of drugs generally. In relation to the advertisement of traditional and herbal 
medicines, it must conform to the Medicines (Advertisement and Sale) Act 1956. For registration 
related matters, the Control of Drugs and Cosmetics Regulations 1984 serves as an important legal 
mechanism. Since the Government has been taking numerous initiatives to assist in developing 
traditional medicines, the National Health Policy on traditional and complementary medicine was 
launched in 2000 with the aim to ensure safety and complementary medicine practices as well as 
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products. 
 
As far as traditional and herbal medicines are concerned, they are required to adhere to the safety 
requirements of the Malaysian Health Ministry’s Drug Control Authority (DCA). The criteria of 
requirements focus on ensuring specific limits for heavy metals and microbial contamination, 
ensuring non-existence of steroids and other adulterants, prohibition of herbs with adverse effect 
and maintaining compliance with Good Manufacturing Practice (GMP). Nevertheless, it is worth 
noting that it is usually a common practice by the local manufacturers and producers of these 
products to register them as supplements. This is due to the fact that generally, registration 
requirements for food supplements are not as stringent as those made applicable for pharmaceutical 
products and hence, many herbal and traditional medicines are registered under the former rather 
than the latter categories. Consequently, there is no need to comply with the above-mentioned 
safety requirement as imposed by DCA. 
 
The National Pharmaceutical Control Bureau (NPCB) as the secretariat of DCA is given the 
responsibility in respect of safety and quality of traditional products. In other words, DCA is the 
main body which is accorded with high responsibility for product registration. In addition, all 
producers of traditional medicine are obliged to comply to adhere to good manufacturing practices. 
The important task undertaken by DCA is to perform lab testing with the primary aim to ensure 
that the heavy metals contained in traditional medicines are within the permissible limits. Besides, 
lab testing is crucial in determining whether the traditional products have been contaminated with 
pathogenic microorganisms or adulterated with scheduled poisons.  
 
In addition, specific tests such as “disintegration and uniformity of weight tests” are also conducted 
out on some specific forms of traditional medicines, namely tablets and capsules (Ministry of 
Health Malaysia, 2018). Thus, it is part of NPCB's obligation to carry out a proper analysis in 
ensuring the content of heavy metals not exceeding the approved limit as stated in Table 1. To 
accomplish this objective, lab testing is inevitable, comprising of both stages of registration (pre 
and post). Public safety issues are always the paramount concern and the Government via NPCB 
is serious in ensuring the safe consumption of traditional products. 
 
 
Table 1: Limit of heavy metals in traditional products  
Heavy metals Toxic effects 
Arsenic NMT 5.0 mg/L or 5.0 mg/kg [5.0 ppm] 
Mercury NMT 0.5 mg/L or 0.5 mg/kg [0.5 ppm] 
Lead NMT 10.0 mg/L or 10.0 mg/kg [10.0 ppm] 
Cadmium NMT 0.3 mg/L or 0.3 mg/kg [0.3 ppm] 
Source: Ministry of Health, Malaysia, 2018 
 
The traditional products which have passed all the test and properly registered are given the 
registration number (MAL number) with hologram. Obviously, if the consumers opt to purchase 
unregistered products with all the claims that might be misleading or simply due to fancy marketing, 
they are exposed to adverse risks and can be fatal.  
 
It is to be noted that there is another important mechanism to ensure consistent adherence to safety 
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and quality of the registered products which is undertaken DCA. It is obliged to carry out as part 
post-market surveillance via sample testing of registered products. For example, it was reported in 
2007 that six product batches were recalled within 72 hours. The total number of registered 
products taken as sampling in that testing exercise was 2,538. It is worth noting that quality defects 
were identified as the main reason for the recall, which also involved a recall within 30 days for 
138 product batches. In terms of categories of medicines being recalled, 12.8% was prescription 
medicines, 9.8% was over-the-counter medicines while the largest percentage came from 
traditional medicines which accounted for 77.4% (Milton, 2008). At this juncture, it is to be noted 
that that the recall rate for traditional medicines is observed to be disproportionate in comparison 
to the percentage of total registered products (46.5%). 
 
Currently, there is an absence of specific guidelines that are compatible for alternative medicine. 
The term ‘alternative medicine’ is meant to consist of formulas that are produced by using herbal 
and natural ingredients. The Malaysian Ministry of Health is fully aware of this situation and hence 
it is working towards establishing a new set of guidelines to cover aspects of clinical trials 
specifically catered for alternative medicine (Shah, 2017). Such an initiative is crucial to encourage 
and thus spur more regulatory approved products. Obviously, the Government is taking into 
account the existing regulation of medicine which is argued to be unsuitable for the herbal and 
traditional medicine. The proposed new guideline is aimed to expedite the normal process taken 
for clinical trials of herbal and traditional medicine. The present regular process usually consumes 
longer time, which may extend to a few years. The new guideline is significant as it would facilitate 
and provide a much feasible avenue for herbal and traditional medicine producers and industry 
players to obtain speedier and easier approval for their products. 
 
 
4. EFFICACY AND SAFETY ISSUES 
 
Traditional and herbal medicines are commonly perceived as being safe and much more effective 
in curing diseases or even as daily supplements because herbs are “natural” substances and hence 
are free from any hazardous chemicals (Manukyan, 2016). After all, the practice of using medicinal 
herbs and remedies as part of cure or treatment has been going on for many years, from one 
generation to another (Sooi & Keng, 2013). Such a perception and trust in traditional medicines 
persists, despite various reports highlighted in mass media about some popular supplements 
exposed for misleading and deceptive claims (Talib, 2006). It is also observed that many consumers 
easily trusted and hence became victims to those irresponsible sellers who do aggressive marketing 
to market their products solely based on testimonies or even unsupported scientific evidence 
(Mydin, 2015). Indeed, intense and reliable research is inevitable to ascertain whether existing 
traditional and herbal products in the market are really safe and efficient as inappropriate use of 
these products have led to dangerous impacts.  
 
Generally, the evidence of the efficacy of traditional and herbal medicines are limited and this 
eventually gives rise to the issue of safety and adverse impact of the use and consumption of those 
products. Those testimonies and therapeutic claims relied on by consumers remain unsubstantiated. 
It is undeniable that there exists some scientific evidence gathered from randomized, scanty clinical 
trials of a small number of herbal medicines. For example, some herbal medicines are found to 
show similar effects like morphine, have been used for to relieve aches and pain. This explains the 
fact that approximately 25% modern medicines at present originate and are produced from selected 
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plants that were inherently used in traditional methods of treatment and hence reflects the 
significance of herbal medicines for proven cure and treatment (Milton, 2008). 
As a matter of fact, there are few ways in which herbal products may produce toxicity. This varies 
from the toxic ingredient exist in some herbs, unintentional substitution of the herb with a toxic 
species, environmental contamination of the herbs to toxicity when taken in combination with 
modern medicines (Hussin, 2001). This in turn explains why herbal remedies are found to have 
toxic “natural” substances. For instance, the rhizome of Smilax luzonensis (akar banar), which is 
usually consumed as an aphrodisiac, to be quite popular among consumers and it is being locally 
sold in supplements with mercury as part of its ingredients (Mydin, 2015). Similarly, a study has 
disclosed that herbal medicines can cause kidney failure and liver damage in some consumers This 
is due to the fact that those herbal medicines or supplements contain toxic chemicals or heavy 
metals, or in some instances, produce harmful reaction when consumed with other drugs (Davey, 
2017).  
 
In this regard, it is observed that there is still a lack of quality control to regulate herbal products, 
in comparison the strict codes which must be complied with by all players in the pharmaceutical 
industry in particular producers and manufacturers. The inherent and persistent risk of microbial 
contamination continues to exist. This can be seen from the fact that from time to time, NPRA has 
been receiving reports of cases involving adverse reactions to alternative medicines which include 
“contamination or substitution with herbs known to be toxic (such as Magnolia, Aristolochia, 
Chapparal), contamination with heavy metals as well as the illegal inclusion of a drug (for example, 
corticosteroids, analgesics, hypoglycemic agents)” (NPRA, 2000). 
  
In terms of manufacturing process, problems also ensued in relation to the quality of manufacturing. 
Whenever the process involves the usage of some plants or herbal substance, the exact amount or 
level of chemical and active ingredients is made dependent on the specific selected variety of plants, 
the ways they are grown and harvested, their processing and manufacturing as well as storage 
methods (Milton, 2008). This is because the concentrations of compounds in these products may 
vary on the basis of the said factors and may give untoward impacts on the ultimate users. 
 
According to the latest report by the Health Ministry of Malaysia, it has taken action based on the 
reports and complaints about traditional medicine products. The Ministry has used its power to 
seize unregistered and counterfeit traditional medicines which amounted to 5,487 products in the 
year 2018 alone. The total value of the seized products was estimated at RM13.1mil. In addition, 
the ministry's Medicine Advertisement Board has also taken a stern action involving 64 cases in 
relation to traditional products with unreasonable, baseless and unsubstantiated claims (Chu, 2018). 
 
 
5. INTERNATIONAL REGULATION: SOME SELECTED JURISDICTIONS 
 
Proliferation of the use and consumption has given rise to an awareness of the potential health and 
safety risks associated with traditional herbal medicine. This in turn prompts regulatory efforts 
worldwide (Colwell, 2016). Though different countries have different ways and legal mechanism 
in regulating this issue, most of them have enacted relevant laws treating traditional and herbal 
medicines as prescription drugs and subjecting them to good manufacturing practices. It is worth 
noting that WHO has made a serious effort in harmonizing and standardizing the regulation of 
herbal medicines globally. To achieve this objective WHO has published some guidelines for 
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herbal medicine safety and efficacy assurance. They include, Quality Control Methods for 
Medicinal Plant Materials (1998), WHO Guidelines on Good Agricultural and Collection Practices 
(GACP) for Medicinal Plants (2003), and WHO Guidelines for Assessing Quality of Herbal 
Medicines with Reference to Contaminants and Residues (2007).  
 
For the purpose of benchmarking and emulating best practices from developed countries, this paper 
will now examine the regulations and legal framework as currently being practised in the European 
Union (EU) and the United Kingdom (UK), Australia and Japan. 
 
5.1.  European Union and United Kingdom 
 
The use of traditional and herbal medicines is widespread in many parts of the world and this 
includes European countries. There have been some reports of potentially life-threatening and fatal 
adverse impacts (Pickup & Hodges, 2002). The escalating concerns over the safety and quality 
issues have paved the ways to strengthen the regulatory mechanism governing such products. As 
such, relevant regulations pertaining to traditional and herbal medicines need to be reviewed for 
the sake of market harmonization of various national herbal regulatory regimes. The registration 
of Traditional Herbal Medicinal Products is now regulated by Directive 2001/83/EC as amended 
by Directive 2004/24/E (Official Journal of the European Union, 2004). The Directive mandates a 
simplified registration procedure for herbal substances, herbal preparations, traditional herbal 
products and their combinations intended for oral, external and/or inhalation preparations, in so far 
as they meet some conditions. 
 
Herbal remedies in the UK have historically been exempted from licensing. According to the 
Human Medicines Regulation (2012), a product comes under the classification of herbal medicines 
“if the active ingredients are herbal substances and or herbal preparations only. Herbal preparation 
is further defined to cover situations when herbal substances are put through specific processes, 
which include extraction, distillation, expression, fractionation, purification, concentration and 
fermentation. The herbal substance being processed can be reduced or powdered, a tincture, an 
extract, an essential oil, an expressed juice as well as a processed exudate (rich protein oozed out 
of its source)”. It is to be noted that not all herbal products would be classified as medicines, as 
some fall within the categories of food supplements or cosmetics.  
 
At present, an application for a traditional herbal registration (THR) in the UK must be 
accompanied with an “evidence that the herbal medicinal product has been traditionally used to 
treat the stated condition for a minimum of 30 years, 15 years of which must have been in the 
European Union (EU)”. This requirement is provided under Directive 2004/24/EC of the European 
Parliament and of the Council. The implementation of the Directive is done via the Medicines 
(Traditional Herbal Medicinal Products for Human Use) Regulations 2005, and came into full force 
on 30 April 2011. Undoubtedly, it has played an important role in establishing a new mechanism 
to facilitate regulatory approval specifically catered for herbal medicines in the UK and across the 
EU. The Traditional Herbal Medicines Registration Scheme is administered by the Medicines and 
Healthcare Products Regulatory Agency (MHRA). To obtain a THR, those interested 
manufacturers, producers or suppliers “must demonstrate a history of traditional use for at least 30 
years (of which generally 15 years must have been in the EU), evidence of safety, adherence to 
appropriate manufacturing standards and provision of appropriate product information to users”. 
The list of herbal medicines which are afforded with THR as issued by MHRA is provided via 
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"Guidance Herbal medicines granted a traditional herbal registration" and is updated regularly. The 
list is very comprehensive, embracing details such as traditional herbal registration (THR) number, 
grant date, registration holder, product name, active ingredient as well as product indications for 
traditional use. 
 
A THR may still be granted in cases of absence of clinical evidence to prove the efficacy of herbal 
medicines provided they meet the EU’s standards of quality and safety, as well as "bibliographic 
or expert evidence demonstrates 30 years of traditional use for the required indication, of which at 
least 15 years must normally have been within the EU". Since the year 2006 when the first THR 
was granted in the UK, the number has shown a steady increase and by the end of 2012, almost 
200 THR has been granted. A product which is granted with THR will be accompanied with a 
Public Assessment Report (UKPAR), and it is available at the MHRA's official website ie at 
“http://www.mhra.gov.uk”. Among the details which are accessible include, "substantial 
information including the Summary of Product Characteristics and images of the label and in-pack 
leaflet, and can be found by entering the product name in the search box". The products in the 
market can easily be recognized via a THR number and a unique ‘THR’ logo printed on the product 
packaging (BHMA, 2018). 
 
It is worth noting that all herbal medicines marketed in the UK since April 2011 need to have either 
a THR or a MA. This is an effective mechanism in ensuring that those medicines comply with all 
the standard and the EU’s strict requirements which are imposed on all medicine in the market 
(BHMA, 2018). In short, the Directive applies to manufactured herbal medicinal products sold 
over the counter, prohibiting the continued sale of unlicensed products. Thus, it has now become 
the practice and the norm in the UK in ensuring a high standard of quality is met, safety level is 
regularly and closely monitored, as well as details of the products are made available to the 
consumers via in-pack leaflets. Ultimately, this assures safety and efficacy of traditional and herbal 
medicines consumed by consumers. 
 
5.2.  Australia 
 
In Australia, the common term which is being used at present is ‘complementary medicines.’ It 
basically refers to “medicinal products containing such ingredients as herbs, vitamins, minerals, 
nutritional supplements, homeopathic and certain aromatherapy preparations.” This type of 
complementary medicines comes under the purview of the Therapeutic Goods Act 1989. Legal 
definition of the term is provided under the Therapeutic Goods Regulations 1990. It includes 
“therapeutic good consisting principally of one or more designated active ingredients” as 
specifically spelt out in Schedule 14 of the Regulations. 
 
In comparison to Malaysia, the EU and the UK, Australia has a slightly unique and different 
approach in regulating traditional and herbal medicine. It is essentially an approach which focuses 
on risk-based, supported with a two-tiered system. The system is comprehensive as it covers 
regulation of all types of medicines, inclusive of complementary medicines. The unique two-tiered 
system apparently consists of; first, lower risk medicines which appear on the list the Australian 
Register of Therapeutic Goods (ARTG); and second, higher risk medicines. The latter category is 
required to be registered on the list of the ARTG. It is to be noted that some complementary 
medicines are not required to be registered and hence are afforded with exemption from the ARTG. 
For example, exemption is given to “certain preparations of homeopathic medicines” (ARCGM, 
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2018). 
 
The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for therapeutic 
goods. TGA undertakes the obligation to carry out a range of evaluation, which includes 
monitoring activities. The main aim is to ensure therapeutic goods on the market meet the required 
standard. Monitoring task also involves the important role of post-market regulatory activities with 
the objective of continuing safety of the listed and registered products. Eventually, the task 
undertaken by the TGA will greatly ensure consumers are provided with therapeutic goods which 
are effective, safe and of high quality.  
 
As part of monitoring processes, the TGA Manufacturing Quality Branch regularly inspects 
manufacturers to ensure compliance with GMP. This is due to the issues such as complementary 
medicines found to have some unexpected and undesirable effects. It is worth noting that the TGA 
has a strong and effective “pharmacovigilance” program. The program focuses on the assessment 
of adverse events that are reported to the TGA by various parties such as consumers, health 
professionals and the pharmaceutical industry. The reports also come from international medicines 
regulators as well as relevant experts which include the medical and scientific experts on TGA 
advisory committees. Concerted effort and full co-operation of all parts of society is the main factor 
in ensuring the success of the “pharmacovigilance” program (ARGCM, 2018). 
 
With regards to matters relating to marketing and advertising of therapeutic goods including 
complementary medicines, there is a legal requirement that it has to be carried out law requires in 
such a way that facilitates promotion of the quality use of the product. Besides, it needs to socially 
responsible to consumers and does not eventually lead to misleading of deception to them (Weir, 
2013). Thus, such an advertisement is made subject to the advertising requirements provided under 
the Therapeutic Goods Act. The Act adopts the Therapeutic Goods Advertising Code (TGAC) and 
other relevant Regulations, in particular the Australian Consumer Law under the Competition and 
Consumer Act 2010. 
 
5.3.  Japan 
 
Japanese traditional medicine could be divided into two main categories, namely folk medicine 
and 'Kampo' medicine. The latter denotes Chinese medicine from ancient China, and uses a formula 
consisting of 5-10 different herbs. More than 95% of Kampo drugs used in Japan are taken as 
ethical drugs (WHO, 1998). Both western herbal medicines and ancient formulations of traditional 
Chinese and Kampo medicines coexist and complement each other to maintain wellness and health. 
Japanese traditional medicine plays an important role as it is regarded as an integrative part, used 
by Western physicians in addition to conventional medicines.  In fact, more than 70% of Japanese 
physicians use Kampo medicine in daily practice together with high-tech medical treatments such 
as organ transplantation and robotic operations (Nishimura, 2009). One of the unique features of 
the Japanese healthcare system, as compared to Malaysian, almost 100% of the Japanese 
population is covered by the National Health Insurance (NHI). This means that Japan practises a 
system for compensating for adverse drug reactions, which is under the administration of Japan’s 
Pharmaceuticals and Medical Devices Agency. 
 
In terms of laws and regulations, traditional and herbal medicines in Japan are heavily regulated in 
a similar manner as conventional pharmaceutical drugs. Majority of herbal formulations are sold 
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as over-the-counter-medications with details provided in the leaflet. Some other herbal 
formulations are sold as prescribed drugs, according to the needs of individual patients. The effect 
of herbal medicines depends entirely on the sum of pharmacological actions of the effective 
ingredients contained in the raw herb. In relation to the evaluation of efficacy and safety, those raw 
herbs which have long been used as folk medicine are listed in the corresponding monograph. For 
example, in the evaluation of efficacy of a Chinese medicine, due consideration is given to the 
empirical facts or experience such as reference data, clinical test reports etc. Generally, specified 
data on safety, stability, comparison with other drugs, clinical test results etc are required to be 
submitted in relation to herbal medicines. 
 
Despite the facts that it is part of Japanese herbal medicines, new Kampo drugs are regulated in 
the same way as Western drugs in Japan. Hence, the time-consuming and expensive chronic 
toxicity tests, special toxicity tests and other related tests are required, inclusive of data for three-
phase clinical trials (WHO, 1998). 
 
All Kampo medicines which are manufactured by Japanese pharmaceutical companies fall under 
the purview of the Pharmaceutical Affairs Law and strictly controlled by Good Manufacturing 
Practice. This legal mechanism is important in ensuring the product quality and safety at its highest 
level (Nishimura, 2009). At this juncture, it to be noted that the Pharmaceutical Affairs Bureau has 
set certain standards for manufacture and quality control of Kampo Drug. The Bureau is obliged 
to ensure that quality of herbs used in each original formula meets precise standards.  
 
Japanese Ministry of Health and Welfare is also responsible in matters related to post marketing 
surveillance. It has three major systems for the collection of domestic adverse reaction data; first, 
the Adverse Drug Reaction Monitoring System under which specific monitoring hospitals are 
designated to report cases of adverse reactions, second, the Pharmacy Monitoring System, and 
third, Adverse Reaction Reporting for Manufacturers. 
 
 
6. A WAY FORWARD – ENHANCING CURRENT LEGAL MECHANISM 
 
6.1.  A Comparative Analysis 
 
Based on the preceding discussion, it is pertinent to make some comparative analysis on the 
relevant legislation of EU, UK, Australia and Japan in comparison to Malaysia. It is observed that 
generally, Malaysia has already in place a workable system of registration in relation to traditional 
and herbal medicines. Nevertheless, there is a real need to address the issues and challenges which 
have been identified, such as adulteration of those products, illegal manufacturing, unregistered 
products as well as slick marketing campaigns involving unsubstantiated testimonials and 
misleading claims (Thevendran, 2015). With the increasing number of traditional and herbal 
medicines in market, consumers are posed with increasing risk of harm if their safety, quality and 
efficacy remained unchecked or unregulated.  
 
In comparison to EU and UK which requires the clinical evidence, there is a gap in Malaysian law 
on that part and hence, adopting some parts of EU Directive 2004/24/E in particular the 
requirement of clinical evidence of efficacy or expert evidence would be an avenue to overcome 
the problem of unsubstantiated testimonials and misleading claims. Despite the fact that DCA does 
202 Suzi Fadhilah Ismail, Ida Madieha Abd Ghani Azmi, Mahyuddin Daud, Juriah Abd Jalil, Sahida Safuan  
 
carry out post-market surveillance, the system could be enhanced by having a strong 
“pharmacovigilance” program as being practiced in Australia. Such a program would facilitate the 
assessment of adverse impacts, but the success of the mechanism is dependent on pro-active efforts 
on the part of consumers, health professionals, the pharmaceutical industry (Marimuthu, 2012). At 
this point, a higher level of awareness need to be raised in accomplishing concerted effort and co-
operation by all parts of society.  
 
In addition, emulating a systematic post marketing surveillance like what is done by Japanese 
Ministry of Health and Welfare would also be a way to enhance the present system in Malaysia. 
The issue of adulteration of traditional and herbal medicines could be tackled by imposing some 
further requirements to the manufacturers and producers on top of existing safety requirements by 
DCA, before they proceed to submit their application for product registration. Additional yet 
critical requirements should include much more detailed and specified data on safety, stability, 
comparison with other drugs, clinical test results etc of the traditional and herbal medicines. It 
might be time-consuming and would implicate additional cost on the part of manufacturers but 
consumers’ safety remains as a primary concern. After all, the system has proved to be working 
well in Australia and other countries, hence there is no reason that it is not feasible in Malaysia. 
 
 
7. CONCLUSION 
 
Enhancing current legal framework and mechanism is inevitable by tightening up the safety 
requirements under DCA, as well as strict adherence to acceptable standards of safety and quality 
as spelt out under policy statements of National Health Policy on traditional and complementary 
medicine. Besides, creating and raising awareness of the health risk to everyone inclusive of 
manufacturers, producers, retailers, and ultimate consumers is vital, so that consumers are fully 
aware of the risk and adverse impacts of unsafe traditional and herbal medicines. This is because, 
other than improving legal mechanism, public education and awareness remains indispensable 
(Talib, 2006). The public must be properly informed and not to fall victim easily by aggressive 
marketing in particular unproven testimonies. A change in mentality is inevitable to minimize the 
gullibility of consumers and eventually ensure that they only choose safe, effective and clinically 
proven products and that if the standard falls short of these, the responsible manufacturers would 
not escape the liability. 
 
The widespread of false, misleading claims and irresponsible aggressive marketing should also be 
curtailed and monitored by responsible authorities, with the help of the public. On this point, there 
is a real need to facilitate the development of responsible advertisement with relevant agencies. 
Once stakeholders learn to fully appreciate that safe traditional and herbal medicine is critical to 
sustaining human health, unwanted adverse impacts can be prevented with greater support and ease. 
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